Sanofi Vaccines US Inc.

Sanofi Vaccines US Inc., a division of Sanofi Pasteur Inc., is a foreign-owned pharmaceutical manufacturer that supplies vaccines and biological products to federal agencies exclusively as a prime contractor, with no subcontracting activity and no set-aside participation. Headquartered in Swiftwater, Pennsylvania, Sanofi Vaccines US Inc. operates under primary NAICS codes 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Biological Product Manufacturing), coded to PSC 6505 (Drugs and Biologicals). The vendor holds approximately 8,210 prime awards with combined potential value of $144.89 billion across 196 distinct customer agencies, establishing it as a mission-critical supplier to the federal vaccine ecosystem.

Sanofi Vaccines US Inc. manufactures and delivers a comprehensive portfolio of vaccines including seasonal and pandemic influenza vaccines, COVID-19 vaccines, pediatric routine immunizations, adult vaccines across all age groups, RSV vaccines, travel vaccines, and specialty vaccines for disease prevention. Representative federal award activity illustrates the vendor's scope: a $2.196 billion Vaccines for Children program indefinite-delivery contract with the CDC through March 31, 2026, supporting pediatric immunization across Medicaid-eligible, uninsured, and American Indian/Alaska Native populations; a $1.882 billion CDC pediatric vaccine IDIQ through March 31, 2027; a $337.56 million CDC pediatric influenza vaccine contract through February 28, 2027; and a $118.93 million CDC adult vaccine IDIQ through June 30, 2027. Significant pandemic preparedness work includes a $79.84 million cost-plus-fixed-fee contract with the Office of the Assistant Secretary for Preparedness and Response for maintaining embryonated egg supply for non-seasonal pandemic vaccine production through January 31, 2028, a $24.87 million clinical trial for Matrix-M adjuvant combined with H5N8 influenza vaccine, and a $19.45 million delivery order for manufacture and stability studies of thimerosal-free pandemic influenza vaccine multidose vials. The vendor also supplies influenza vaccines to the Defense Logistics Agency ($25.06 million single-award IDIQ through February 13, 2026, with multiple task orders totaling $16.8 million), the Department of Veterans Affairs ($8.67 million influenza vaccine contract through March 14, 2027), and the Bureau of Prisons through a $8.67 million influenza vaccine IDIQ serving federal correctional facilities nationwide.

Customer concentration reflects deep market positioning in federal health security. The top five customer agencies by potential value account for 43 percent of the vendor's combined potential value: CDC Pittsburgh leads with $34.65 billion across 75 awards (primarily the Vaccines for Children program and seasonal vaccine vehicles), followed by the Office of the Assistant Secretary for Preparedness and Response with $24.15 billion across 105 awards (pandemic preparedness and medical countermeasures), Veterans Health Administration's Veterans Integrated Service Network 12 with $2.93 billion across 114 awards, Defense Logistics Agency Troop Support Medical with $229.4 million across 728 awards, and Indian Health Service with $34.8 million across 50 awards. By award count, the Navy Bureau of Medicine and Surgery leads with 1,217 awards worth $33.2 million, Defense Logistics Agency Troop Support Medical places second with 728 awards worth $229.4 million, and the Army, broader Defense Logistics Agency, and Department of Veterans Affairs follow. This divergence signals that while BOP/military placement frequency is high (many small routine delivery orders), dollar concentration anchors to CDC's large multi-billion-dollar Vaccines for Children and pandemic preparedness vehicles and HHS preparedness contracting.

The vendor holds five principal parent vehicles on which it receives task orders: two GSA Federal Supply Schedules (V797P5245X carrying 1,779 task orders valued at $27 million, and V797P5949X carrying 1,341 task orders valued at $52.8 million for Pharmaceuticals and Drugs), and three indefinite-delivery contracts (VA797P0205 carrying 254 task orders valued at $29.8 million, VA797P0260 carrying 218 task orders valued at $19.3 million, and V797P9170 carrying 182 task orders valued at $115.1 million). These vehicles enable streamlined procurement across civilian and defense agencies for routine seasonal vaccines and emergency pandemic supply.

Activity has been cyclical year over year—55 awards in 2022, rising to 153 in 2023, declining to 117 in 2024, dipping to 59 in 2025, and recovering to 123 in 2026 through mid-October. This pattern reflects seasonal influenza procurement peaks and periodic re-competition of large CDC and Defense vehicles. Of combined potential value, only $18.18 billion (13 percent) has been obligated, indicating substantial pipeline value in indefinite-delivery vehicles pending task order issuance. Twenty awards with ultimate completion dates within the next twenty-four months carry combined potential value of $142.3 million and face recompete exposure; these are predominantly routine influenza vaccine delivery orders under existing CDC and VA IDIQs scheduled to complete between September 2026 and March 2027.

Service Contract Inventory captures minimal federal service activity: only $30.5 million in SCI-reportable invoiced revenue across 17 records (FY2022–FY2025), reflecting 0.9 FTEs in FY2022 and 0.8 FTEs in FY2024, with zero FTE-reportable service revenue in FY2023 and FY2025. Government-paid rates on SCI records run a broad spectrum—10th percentile $1,402.83 per hour, median $7,221.10 per hour, 90th percentile $10,742.95 per hour—signaling mix of administrative and specialized scientific labor. Across SCI-reportable prime contracts, the vendor performs zero subcontracted hours, consistent with its pure-prime operating model across the federal award footprint.

Sanofi Vaccines US Inc. operates as a wholly owned division of Sanofi Pasteur Inc., a Swiftwater-based foreign-owned pharmaceutical manufacturer with SAM.gov registration dating to 2002. The vendor holds a named subsidiary, Dynavax Technologies Corporation, a for-profit foreign-owned business entity. Sanofi Vaccines US Inc. competes exclusively full-and-open across federal agencies without socioeconomic set-aside participation and maintains an established track record fulfilling large-scale federal vaccine supply requirements across civilian health agencies, the Veterans Health Administration, Department of Defense, and federal correctional system beneficiaries. No subcontracting activity appears in the award footprint; the vendor builds and performs all federal work with internal resources and manufacturing capacity.